QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

20,995 signal articles · 493 in last 24h · 103,318 total before filter · latest 1h ago
493last 24h
2476last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
AllMacro242Earnings1457M&A138Regulatory16Product4Analyst29
✕ clear all filtersticker: CVSsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
CVS Stock Down On Early Warnings About 2027
The Wall Street Journal1h agoneutral
CVS Stock Down On Early Warnings About 2027

CVS Health saw its shares dip about 6% even though it handily beat Wall Street’s expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company’s unusually early commentary about 2027.

Bloomberg9d agoneutral
Morgan Stanley’s Wilson Says AI Adoption Key to Profit Outlook

(Bloomberg) -- US companies that are integrating artificial intelligence capabilities are well positioned this earnings season as they’re poised for stronger profit margins, according to Morgan Stanley strategists.Most Read from BloombergDeepSeek Suspends Fundraising After Viral US-China PostsUS, Iran Extend Pause in Strikes as Oman Holds Hormuz TalksSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysChina Chipmaker CXMT Jumps 466% in Debut After Blockbuster IPOStocks, Bonds Rise in Re

CVS Group Q4 Earnings Call Highlights
MarketBeat12d agoneutral
CVS Group Q4 Earnings Call Highlights

CVS Group (LON:CVSG) said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiterate its capital allocation policy and outline expected returns from acquisitions and capital invest

In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s
The Wall Street Journal21d agoneutral
In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com21d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks
Barrons.com23d agoneutral
Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks

After a rocky start to the year, health insurer stocks have roared back. The insurers are trying to end a difficult cycle that began about three years ago, when healthcare use, and the costs to cover it, accelerated postpandemic. The fund’s top 10 holdings encompass six health insurers, three of which— UnitedHealth Group Aetna parent CVS Health and Elevance Health —comprise more than 40% of the fund.

Bloomberg41d agoneutral
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

Closed Rite Aid stores get surprising retail replacement
TheStreet52d agoneutral
Closed Rite Aid stores get surprising retail replacement

When Rite Aid, a major pharmacy retailer, filed for Chapter 11 bankruptcy a second time in 2025, it led to the shuttering of its 1,250 locations. Over time, many were sold to competitors like CVS and Walgreens, and some spaces were taken up by retailers such as Kroger and Albertsons. But some ...

CVS Health (CVS): Buy, Sell, or Hold Post Q1 Earnings?
StockStory54d agoneutral
CVS Health (CVS): Buy, Sell, or Hold Post Q1 Earnings?

Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $100.39, representing a healthy 26.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound
The Wall Street Journal68d agoneutral
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

CVS brings back coverage for Lilly's obesity drug Zepbound
Reuters69d agoneutral
CVS brings back coverage for Lilly's obesity drug Zepbound

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Amazon looks to redefine a need for speed with 30-minute deliveries
Associated Press85d agoneutral
Amazon looks to redefine a need for speed with 30-minute deliveries

More than 20 years after it redefined fast shipping, Amazon is preparing to raise the bar on consumer expectations again by offering to fulfill customers' most urgent product needs in a half-hour or less for an extra fee. The company, which revolutionized online shopping in 2005 with two-day deliveries for Prime members, is rapidly opening small order-processing hubs in dozens of U.S. and foreign cities to cater to shoppers who can't or don't want to wait for cough medicine to relieve flu symptoms or tomatoes for tonight's dinner salad. The ultrafast service, called Amazon Now, first launched in India last June.